NCT05822180View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Nano-S1

PHASE3CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 1, 2022

Study Completion Date

February 20, 2022

Conditions
COVID-19 Pneumonia
Interventions
DRUG

NANOS1 , argent colloïdal ,

orally, during 5 day

Trial Locations (1)

2034

Agili Faida, Tunis

All Listed Sponsors
lead

General Administration of Military Health, Tunisia

NETWORK

NCT05822180 - Evaluation of the Efficacy and Safety of Nano-S1 | Biotech Hunter | Biotech Hunter